Pimavanserin for rigid-compulsive symptoms in autism
Part of Mental health clinical trials.
This trial tests if the drug pimavanserin can help reduce rigid or repetitive behaviors in people with autism spectrum disorder. It may be an option if you or your child struggle with these symptoms and want to try a new treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 to 40 years old.
- You must have a diagnosis of autism spectrum disorder (confirmed by a doctor).
- Your repetitive behaviors must be moderate or severe (score 4 or higher on a doctor's rating scale).
- You must have a non-verbal IQ of 70 or higher.
- You must live with a parent or caregiver who can spend at least 4 hours a day with you and help answer questions.
- You cannot be taking certain medications like antidepressants (SSRIs) or antipsychotics, and must not have changed any psychiatric medications in the last 2 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether buspirone, a medication that helps with anxiety, can reduce anxiety in children and teens with autism. It is a 12-week study where participants receive buspirone or a placebo (a pill with no medicine) to see if it improves anxiety symptoms.
This trial studies whether N-acetylcysteine, a medicine taken by mouth, can improve autism-related restricted and repetitive behaviors in children. It looks at children who are showing at least moderate severity in these behaviors and may involve brain testing for safety reasons.
This trial tests an oral liquid medicine (called NTI164) to see if it helps reduce symptoms of autism in children and teens. It may be an option if current treatments haven't fully helped, but it requires regular study visits and certain health rules.
This Phase 2 study tests whether a single dose of N-acetylcysteine can improve “restricted and repetitive behaviors” in children with autism. It’s meant for kids who are stable and still in early puberty stages.
This study tests whether a low-dose buprenorphine skin patch can help reduce symptoms of autism spectrum disorder in children and teenagers. It aims to see if the patch is safe and effective when used in addition to usual care.
This trial tests whether a specific supplement can help adults with Level 1 autism. It is open only to Italian-speaking participants aged 18–35 who do not have other major mental health or brain conditions.
Hear when a new Autism spectrum disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.